Quick answer
Wellorithm advertises compounded semaglutide from $147 and compounded tirzepatide from $249, but those figures appear in a first-month promotional campaign and the normal compounded renewal prices are not clearly disclosed.
Its branded pages show Wegovy at $899 per month and Mounjaro at $1,399 per month. The Ozempic and Zepbound pages each display conflicting prices of $1,119 and $1,199 per month, so neither figure should be treated as definitive until checkout.
Wellorithm’s terms describe recurring billing every 28 days. That can produce 13 billing cycles over 364 days rather than 12 calendar-month charges.
Affiliate disclosure: Care Path Compare may receive compensation if you use a Wellorithm link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.
Advertised prices
| Pathway | Advertised price | Important qualification |
|---|---|---|
| Compounded semaglutide | From $147 | First-month promotion; normal renewal and formulation-specific pricing unclear |
| Compounded tirzepatide | From $249 | First-month promotion; normal renewal and formulation-specific pricing unclear |
| Wegovy | $899/month | Verify final checkout total, availability, billing cadence, and inclusions |
| Mounjaro | $1,399/month | Verify first-order discount, availability, billing cadence, and indication-specific prescribing |
| Ozempic | $1,119 or $1,199/month | Two conflicting figures appear on the same provider page |
| Zepbound | $1,119 or $1,199/month | Two conflicting figures appear on the same provider page |
Prices were checked August 3, 2026 and may change.
Why the compounded prices are not ongoing-price comparisons
The $147 and $249 figures are tied to campaign language advertising $100 off the first month. Wellorithm does not clearly publish the standard renewal amount for each compounded formulation.
Until those renewal prices are confirmed, these figures should be treated as promotional entry prices rather than stable monthly totals. They should not determine Wellorithm’s placement in a lowest-ongoing-price table.
Every-28-day billing
Wellorithm’s terms describe recurring billing every 28 days. A 28-day cycle can result in 13 charges across 364 days. Confirm the exact billing interval and next charge date before paying.
Shipping, taxes, labs, and other possible costs
Marketing pages say free shipping or free expedited shipping and often use no-hidden-fee language. The formal terms say prices exclude shipping and taxes. Because those statements conflict, rely on the final checkout agreement.
Public materials reviewed did not clearly establish whether laboratory testing is required, whether laboratory costs are included, whether supplies are included for every pathway, or whether dose changes affect compounded prices.
Cancellation and refund exposure
The terms describe cancellation by email for future billing cycles and say processed payments are nonrefundable. Confirm how much notice is required, whether cancellation stops an order already sent to a clinician or pharmacy, and what happens financially if no prescription is issued.
Questions to verify before checkout
- What is charged today?
- What is the normal renewal amount?
- Is billing every 28 days or monthly?
- Which formulation is included?
- Does the price change with dose?
- Are clinician visits, supplies, shipping, taxes, and labs included?
- Which pharmacy will dispense the prescription?
- What is the cancellation deadline?
- When does the current payment become nonrefundable?
- What happens if the clinician does not prescribe?
Bottom line
Wellorithm publishes enough information to compare promotional and branded prices, but it does not yet provide a clean ongoing-cost picture for compounded semaglutide or tirzepatide. Its Ozempic and Zepbound pages also contain conflicting figures.
Use the advertised numbers as a starting point, not a final quote. Confirm the recurring charge, billing interval, formulation, pharmacy, shipping, labs, and cancellation terms before paying.
Affiliate disclosure: Care Path Compare may receive compensation if you use this provider link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.
Important information
Official sources
- Wellorithm, default GLP-1 campaign, accessed August 3, 2026.
- Wellorithm, terms and conditions, accessed August 3, 2026.
- Wellorithm, branded medication pages, accessed August 3, 2026.
- U.S. Food and Drug Administration, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.